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Background: MicroRNAs (MiRNA) are small non-coding RNAs that regulate gene expression. The aim of this study
was to identify miRNAs differentially expressed between mild and moderately emphysematous lung, as well as their
functional target mRNAs. Resected lung from patients with COPD undergoing lung cancer surgery was profiled
using miRNA (Agilent Human miRNA profiler G4470 V1.01) and mRNA (OperonV2.0) microarrays. Cells of lung origin
(BEAS-2B and HFL1) were profiled using mRNA microarrays (Illumina HumanHT-12 V3) after in vitro manipulation.
Results: COPD patients had mean (SD) age 68 (6) years, FEV1 72 (17)% predicted and gas transfer (KCO) 70 (10)%
predicted. Five miRNAs (miR-34c, miR-34b, miR-149, miR-133a and miR-133b) were significantly down-regulated in
lung from patients with moderate compared to mild emphysema as defined by gas transfer (p < 0.01). In vitro
upregulation of miR-34c in respiratory cells led to down-regulation of predicted target mRNAs, including SERPINE1,
MAP4K4, ZNF3, ALDOA and HNF4A. The fold change in ex-vivo expression of all five predicted target genes inversely
correlated with that of miR-34c in emphysematous lung, but this relationship was strongest for SERPINE1 (p = 0.05).
Conclusion: Differences in miRNA expression are associated with emphysema severity in COPD patients. MiR-34c
modulates expression of its putative target gene, SERPINE1, in vitro in respiratory cell lines and ex vivo in
emphysematous lung tissue.
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MicroRNAs (miRNAs) are regulators that modulate tran-
scription and translation of target mRNAs. There are over
1,000 miRNAs encoded within the human genome and
these miRNAs are estimated to target ~60% of genes. The
discovery of miRNAs has introduced a new level of com-
plexity to be considered for every biological process. MiR-
NAs are implicated in normal biological functioning,
including development, differentiation, homeostasis and
apoptotic cell death [1]. Their dysregulation leads to dis-
ease processes including malignancy [2-5], inflammation
[6,7] and heart disease [8].
MiRNAs are mediators of inflammation [9], an impor-
tant mechanism driving chronic obstructive pulmonary* Correspondence: ss.francis@uqconnect.edu.au
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distribution, and reproduction in any mediumdisease (COPD) development and progression. Several
miRNAs have been implicated in lung disease [10]. Expo-
sure to cigarette smoke extract (CSE), diesel exhaust parti-
cles (DEP) and lipopolysaccharide (LPS) induce changes
in lung expression of several miRNAs including miR-26b,
miR-31, Let-7a and miR-192 [10]. MiRNAs associated
with asthma include miR-21, miR-126, miR-133a, miR-
148a/b and miR-152 [11]. Other miRNAs are associated
with the inflammation observed in idiopathic pulmonary
fibrosis (IPF) [12] and cystic fibrosis [13], and many stu-
dies implicate miRNAs in the pathogenesis of lung cancer.
Collectively these studies demonstrate that miRNAs are
expressed in the lung and are involved in the pathogenesis
of lung disease.
COPD prevalence is continually increasing and it is
predicted to become the third leading cause of death
worldwide by 2020 [14,15]. COPD is under-diagnosed,
since patients are most often diagnosed only when the
disease is advanced, too late for prevention, and when
there is no curative intervention. Better screening toMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gression to severe COPD are urgently needed to improve
COPD outcomes. Genomic tools provide an opportunity
to improve our understanding of the pathogenesis of
COPD and translate this to enhanced clinical manage-
ment [16]. Current understanding of COPD pathogenesis
is that lung injury by inhaled tobacco results in depletion
of lung alveolar tissue, large and small airway inflamma-
tion, fibrosis of small airways and mucus hypersecretion
contributing to small airway obstruction. Inflammation is
the main cause of lung tissue destruction and provokes
defense mechanisms associated with tissue repair [17].
Given the role of miRNAs in lung inflammation and the
lung’s response to inhaled toxins, miRNAs are likely to be
involved in pathogenesis and/or progression of COPD.
Furthermore, miRNAs regulate mRNA expression, and
mRNA (transcriptome) profiles relevant to COPD patho-
genesis have been identified [18-23]. MiRNA profiles in
lung from patients with COPD have shown differences in
miRNA expression in relation to susceptibility to COPD
[24,25], when comparing moderate/severe COPD patients
with non-COPD subjects [24,25]. Here we aimed to iden-
tify lung miRNAs associated with COPD severity, and
demonstrate miRNA regulation of genes that may be im-
plicated in the progression of COPD.
Methods
Participant selection
This study was approved by the Human Research Ethics
Committees of The University of Queensland and The
Prince Charles Hospital (TPCH). Lung tissue samples
from 29 patients with COPD undergoing curative resec-
tion for lung cancer were selected from the TPCH tissue
bank. Written informed consent was obtained from all
patients prior to surgery. Detailed information on sub-
ject selection, and inclusion and exclusion criteria are
listed elsewhere [18]. Briefly, smokers with at least a 20
pack year history who quit smoking at least 10 months
prior to surgery, not currently on inhaled or oral ste-
roids, and without other lung pathology that may con-
found spirometry measurements, were considered. All
had FEV1/FVC (or FEV1/VC) ratio <0.70, indicating the
presence of COPD. Twenty-nine former smokers with
COPD (the ‘TPCH-KCO set’) were selected and classi-
fied by gas transfer measurements (single breath carbon
monoxide diffusion coefficient, KCO) as “mild” emphy-
sema (>75% predicted KCO) and “moderate” emphy-
sema (40-75% predicted KCO).
miRNA isolation, hybridization and data extraction
Total RNA was isolated from 30-45 mg of non-tumour
lung tissue using Trizol (Invitrogen). DNA was removed
using an Ambion DNA-free™ kit (Ambion, Foster City,
CA, USA) following the manufacturer’s instructions. Theresulting total RNA was cleaned using the DNeasy
miRNA clean up kit (QIAGEN, Valencia, CA, USA) fol-
lowing manufacturer’s instructions. Purified RNA was
quality checked using a Bioanalyzer Agilent Technologies,
Santa Clara, CA, USA), based on the presence of miRNAs
determined using a small RNA analysis kit and distinct
18S and 28S peaks determined by an mRNA analysis kit.
Agilent human miRNA oligo arrays (8×15K array, Part
No. G4470A, Agilent Technologies) based on miRBase
V9.1 were used. This array contains 15,744 elements
representing 470 human miRs and 64 viral miRs. The
experiments were performed according to the manufac-
turer’s instructions. Briefly, 100 ng of total RNA from lung
tissue was dephosphorylated using calf intestine alkaline
phosphotase to create sticky ends for ligation of the fluo-
rescent dye pCp-Cy3 and T4 RNA ligase (GE Healthcare,
Little Chalfont, England). The resulting labeled RNA
was purified using Micro-bio spin 6 columns (Bio-Rad,
Hercules, CA, USA) to remove unlabeled dye and then
hybridized to the Agilent microarray slide for 20 hours at
55°C. The slides were washed to remove any unbound
RNA and images were captured using Agilent microarray
scanner. Raw features were filtered for spot quality,
averaged and extracted using Agilent feature extraction
software. The missing values were filled in using the
K-nearest neighbor algorithm in Avadis (Strand Life Sci-
ences, Bangalore, India). Study design for microarray exper-
iments satisfied the MIAME guidelines (http://www.mged.
org/Workgroups/MIAME/miame_checklist.html). The re-
ferred data has been deposited in the Gene Expression
Omnibus (GEO) (GSE33338 http://www.ncbi.nlm.nih.gov/
gds/?term=GSE33338).
Candidate miRNA selection and technical validation using
qRT-PCR
miRNAs differentially expressed between mild and mod-
erate classes of emphysema lungs were identified by class
comparison analysis in BRB-ArrayTools V4.2 (developed
by Dr Richard Simon and Amy Peng Lam, freely access-
ible at http://linus.nci.nih.gov/BRB-ArrayTools.html). A
P value of <0.01 and false discovery rate (FDR) of <0.05
were used as selection criteria for significance. Two miR-
NAs were randomly chosen for technical validation by
quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR) using TaqMan microRNA assays (Applied
Biosystems, Foster City, CA, USA). The geometric mean
(GeNorm [26]) of two small RNA housekeepers, U6 and
RNU48, were used for normalization [26,27].
Identifying genes modulated by miR-34c using in vitro
techniques
mRNAs targets of altered miRNA expression in com-
monly used lung cell lines were identified using in vitro
techniques.
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Commercial lung cell lines BEAS-2B [28] (CRL-9609, a hu-
man bronchial epithelial cell line) and HFL1 [29] (CCl-153,
a human fetal lung fibroblast cell line) were purchased
from ATCC (Virginia, USA). The cell lines were grown as
per the supplier’s recommendations. BEAS-2B and HFL1
were cultured in RPMI and DMEM, respectively, supple-
mented with antibiotics and 10% FCS and incubated in
5% CO2.
Transfection conditions
A microRNA (miR-34c) that technically validated and
displayed high fold change difference between em-
physema classes was chosen for this purpose. Pre-miR™
miRNA precursor molecules (Invitrogen by Life Sciences,
Carlsbad, CA) for miR-34c-5p were used to increase
the expression of the miR-34c in HFL1 and BEAS-2B
lung cells and the expected increase in expression of
miR-34c was confirmed using TaqMan microRNAs as-
says (Invitrogen by Life Sciences, Carlsbad, CA). The
-5p isoform of miR-34c-5p represents the 5′ arm of the
hairpin precursor of the mature miRNA from which
the mature sequence has been excised. The probe se-
quence represented on the microarray was derived
from the miR-34c-5p sequence. Optimal conditions
were tested and selected based on the manufacturer’s
instructions. Briefly 50,000 cells were transiently trans-
fected with 20nM pre-miR precursor molecules and
NeoFX transfection reagent for 24 hours. The transfec-
tion was conducted twice in triplicate each time on
two different days two weeks apart. The triplicates
were combined for the arrays to provide enough total
RNA for the assay.
mRNA isolation, hybridization and data extraction
Total RNA was extracted and purified from cell lines,
BEAS-2B and HFL1, after transfection, using RNeasy
Mini kit and RNAse free DNAse kit (QIAGEN, Hilden,
Germany). Microarray expression profiling was con-
ducted on the purified RNA using Illumina HT12V3
whole genome gene expression arrays, according to the
manufacturer’s instructions. The array contains 48,000
elements representing over 25,000 annotated genes
from the RefSeq (Build 36.2) and Unigene databases
(Build 199). Element features were extracted using the
gene expression module of the BeadStudio V1.1.1 soft-
ware (GenomeStudio, Illumina, Hayward, CA). Raw
features were normalized to the 75th percentile of all
elements in GeneSpring GX V9 (Agilent Technologies,
CA, USA). Missing values were filled in using the
K-nearest neighbor algorithm in Avadis (Strand Life-
Sciences, Bangalore, India). Differentially expressed
genes were identified using class comparison analysis in
BRB-ArrayToolV4.2.Identification of miR-34c predicted targets
The genes differentially expressed between miR-34c trans-
fected and non-transfected cells were compared to the pre-
dicted targets of miR-34c from the TargetScan and PicTar
databases. Candidate target genes whose expression were
negatively correlated to that of miR-34c in vitro (in cell
lines) and ex vivo (in lung of TPCH-KCO and Spira et al.
[19] subjects) were identified. Therefore, identified genes
were biologically validated in the original TPCH-KCO [18]
samples (used to develop microRNA profiles) by qRT-PCR
using pre-designed gene expression assays (Applied Biosys-
tems, Foster City, CA, USA). The raw expression was nor-
malised to the house-keeping gene, GAPDH.
Results
Identification of miRNAs associated with emphysema
severity using microarrays and confirmation by qRT-PCR
Agilent human miRNA oligo 8 × 15 K array experiments
were conducted on samples of lung from patients with mild
(>75% predicted KCO, n = 9) or moderate emphysema
(40 to 75% predicted KCO, n = 20). Demographic data are
shown in Table 1. After preprocessing of the raw signals,
228 miRNAs were detected in at least 50% of the lung sam-
ples. Duplicate array data for these 228 miRNAs were
highly correlated (r2 =0.98, Additional file 1: Figure S1).
Class comparison identified five miRNAs (miR-34c, miR-
34b, miR-149, miR-133a and miR-133b) that were signifi-
cantly differentially expressed between mild and moderate
emphysema (p < 0.01, Additional file 1: Figure S2 & Table 2).
All five were expressed at lower levels in lung from patients
with moderate emphysema, compared with lung from pa-
tients with mild emphysema. In this cohort, expression of
three of these miRNAs (miR-149, miR-133a and miR-133b)
correlated with functional measurement of emphysema se-
verity (KCO, Figure 1). MiR-34c expression exhibited the
greatest difference between groups with 0.3 fold lower ex-
pression in the moderate severity group. qRT-PCR con-
firmed similar fold differences in expression to microarray
results for the two miRNAs, miR-34c and miR-133a tested
(Additional file 1: Figure S3). A flow diagram describing the
methods is shown in Additional file 1: Figure S4.
Effect of miR-34c-5p over-expression on its predicted
mRNA targets in respiratory cells in vitro using gene
expression microarrays
To identify mRNA targets regulated by miR-34c in lung
cells, we transfected miR-34c-5p precursor into BEAS-2B
and HFL1 cells, and demonstrated the expected 95-99% in-
creased expression of miR-34c by qRT-PCR (data not
shown). Illumina HumanHT12 V3 transcriptome microar-
rays were then used to examine the expression of mRNAs
in miR-34c-transfected cells, relative to cells transfected
with scrambled sequence controls. Class comparison
analysis in BRB-ArrayTools V4.2 identified 2,152 elements
Table 1 Demographics of the TPCH-KCO set (n = 29 patients)







Age (Mean ± SD yrs) 70 ± 4 67 ± 7
Range 63-74 53-78
Male/Female 7/2 14/6
FEV1 % predicted (Mean ± SD) 80 ± 17 68 ± 15
Range 52-107 50-97
FEV1/VC (Mean ± SD) % 59 ± 5 54 ± 14
Range 50-70 40-70
KCO % predicted (Mean ± SD) 79 ± 3 66 ± 9
Range 75-85 38-74
Pack years (Mean ± SD) 62 ± 34 75 ± 49
Range 28-135 24-240





GOLD Stage I Mild (FEV1 ≥80% predicted) 4 3
GOLD Stage II Moderate (50 < FEV1 < 80%
predicted)
5 17
List of abbreviations, FEV1 forced expired volume in one second, VC vital
capacity, KCO transfer coefficient of carbon monoxide, SD standard deviation,
LLL left lower lobe, RLL right lower lobe, LUL left upper lobe, RUL right upper
lobe, RML right middle lobe, LL left lung, RL right lung.
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miR-34c (p < 0.001) in BEAS-2B and HFL1 cell lines, the
vast majority of which (90%) were down-regulated by ele-
vated miR-34c levels. Among the 2,152 genes, fifty were
predicted as miR-34c targets by the databases Pictar and
TargetScan-and they were significantly down-regulated
(>1.8 fold down-regulation) in the transfectants. We next
examined ex vivo expression patterns of the genes found to
be miR-34c responsive in vitro. Of the fifty genes, thirty-
three were represented in the filtered TPCH-KCO dataset
[18] and thirty-two in the dataset of Spira et al. [19].Table 2 Demographics of miRNAs significantly downregulate
mild emphysema patients




hsa-miR-149 0.001 0.019 13.60
hsa-miR-133a 0.002 0.019 35.66
hsa-miR-133b 0.003 0.019 49.72
hsa-miR-34c 0.006 0.034 57.53
hsa-miR-34b 0.008 0.034 185.4In both of these datasets, five genes (MAP4K4, SER-
PINE1, ALDOA, HNF4A and ZNF3) were expressed at
higher levels in lung from patients with moderate or
severe emphysema compared with lung from normal
subjects or subjects with mild emphysema, whereas ex-
pression of miR-34c was reciprocal (Figure 2), consistent
with the possibility that these five genes may be regu-
lated by miR-34c in emphysema. In the 29 ex vivo lung
samples used for miRNA microarray profiling, qRT-
PCR confirmed that expression of both SERPINE1
(fold-change >2.2) and HNF4A (fold-change >1.3) had
generally higher expression in association with lower
miR-34c expression; however only SERPINE1 (p = 0.05)
was significantly differentially expressed between mild
and moderate emphysema (Figure 3) in this cohort,
and it was correspondingly upregulated in more severe
disease in both TPCH-KCO (fold change >1.2, p < 0.05)
and Spira (fold change >1.13) datasets (Figure 2).
Discussion
MiRNAs regulate the expression of genes involved in bio-
logical processes relevant to the progression of chronic
lung disease, including cellular stress, cell differentiation
and apoptosis [30-32]. Here, we aimed to identify miRNAs
(and their target mRNAs) associated with emphysema
severity in COPD patients. Five miRNAs were identified
to be significantly down-regulated in lung from patients
with moderate emphysema, compared with lung of mild
emphysema patients. In addition, a negative correlation
was noted in the expression of these miRNAs and their
putative target mRNAs ex vivo. Furthermore, increasing
the expression of miR-34c (the miRNA with the largest
fold change between the mild and moderate emphysema
patient groups) in respiratory cells resulted in decreased
expression of predicted mRNA targets in vitro, providing
additional functional expression data. Our data suggest
modulation of SERPINE1 by miR-34c in vitro and ex vivo.
Dysregulation of SERPINE1 by miR-34c could therefore be
a potential mechanism involved in emphysema severity
and progression. To our knowledge, this is the first study
to compare miRNA profiles in the lungs of COPD patients











miRNA p R2 Fold change (ratio 
moderate/mild 
emphysema)
miR-34c 0.07 0.11 0.36
miR-133a 0.007** 0.239 0.55
miR-149 0.005** 0.255 0.56
miR-133b 0.02* 0.185 0.55
miR-34b 0.276 0.044 0.42
Figure 1 Correlation plots of the five candidate miRNAs and emphysema status. The expression of the differentially expressed microRNAs
for the 29 patients and their emphysema status (KCO% predicted corrected for hemoglobin) is shown. The correlation of miR34c expression
determined by microarrays in lung tissues to its consequent KCO measurements were not significant (p > 0.05). However this miRNA was chosen
for cell line studies as it portrayed siginificant difference in gene expression between patient groups i.e. moderate vs mild emphysema lungs. MiRNA
levels ofthe 29 samples are drawn on the X-axis, KCO% predicted on the left Y-axis and microRNA expression on the right Y-axis. * indicates a
correlation of significance p < 0.05 and ** indicates a correlation of significance p < 0.01.
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relate miRNA-mediated mRNA regulation in the same
lung samples. It is known that miRNAs mediate gene
silencing through translational inhibition and mRNA deg-
radation. In addition, target mRNA is degraded in more
than one third of genes that display translational repres-
sion [33]; hence we have focused on studying changes in
mRNA expression as a consequence of altered miRNAexpression. MiRNAs that are down-regulated in a certain
disease state (e.g. moderate emphysema, compared to
mild emphysema) would be expected to upregulate ex-
pression of their predicted mRNAs, in an orchestrated
process of epigenetic regulation. This relationship of
miRNA and mRNA expression has been demonstrated
previously in airways from COPD patients [25] but not in

































mRNA expression of the fives genes in ex-vivo 
lung tissue samples where the initial miRNAs were 
recorded
mRNA expression of the fives genes in in-vitro in
respiratory cell-lines
ii)i)
Figure 2 Histogram of in vitro (i) and ex vivo (ii) expression of genes predicted and modulated by miR-34c over-expression in BEAS-2B
and HFL1 cell lines. Ratio of moderate to mild gene expression of emphysema patients are shown on the Y-axis and the genes on the X-axis.
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in lung between moderate vs mild emphysema patients in
this study, miR-34c is particularly relevant to human lung
disease, as its expression is increased during normal lung
development [34]. We found decreased expression of
miR-34c in lungs of patients with moderate emphysema,
compared to mild emphysema. Van Pottelberge et al. also
found greater than three-fold downregulation of miR-34c
in sputum from smokers with COPD, compared to those
without COPD, and a direct correlation between miR-34c
























Figure 3 Histogram of qRT-PCR measurements of miR-34c
regulated targets in TPCH-KCO dataset. Genes differentially
expressed between transformed and scrambled sequence controls
in respiratory cell lines were independently tested in TPCH-KCO
dataset using qRT-PCR. This step minimizes false positives and
ensures that authentic genes are discovered. Average gene expression
in mild and moderate emphysema lungs are represented in the Y-axis
and genes on the X-axis. SERPINE1 was significantly upregulated in
emphysema lungs. HNF4 was also upregulated but did not
attain significance.findings support our study, since there was down-
regulation of miR-34c expression in their COPD patients,
compared to controls, and also down-regulation in our
moderate emphysema patients, compared to mild emphy-
sema, indicating a similar continuum of expression with
increasing disease severity. In the setting of reduced miR-
34c expression in moderate emphysema lung (vs mild), we
were able to confirm increased gene expression of two of
its predicted mRNA targets, HNF4 and SERPINE1.
HNF4A (hepatocyte nuclear factor 4A) is a transcription
factor that regulates the expression of cytokines involved
in inflammation, as demonstrated in other organs (e.g. kid-
ney [35]); its role in the lung is yet to be determined. SER-
PINE1 (Serpin Peptidase Inhibitor, Clade E (Nexin,
Plasminogen Activator Inhibitor Type 1), Member 1), also
known as plasminogen activator inhibitor 1 (PAI-1), is a
protease inhibitor, and inhibitor of fibrinolysis. PAI-1
knockout mice demonstrate emphysema-like changes in
the lung [36], so our findings of increased SERPINE1 ex-
pression in moderate emphysema (vs mild emphysema)
may be unexpected, given the role of protease-antiprotease
imbalance in the pathogenesis of emphysema. However,
SERPINE1 is only one of a number of antiproteases, and
has other roles in the lung that could be relevant to the
progression of emphysema. For example, SERPINE1 has
been shown to be upregulated in the lung or lung cells
during hypoxia [37], exposure to lipopolysaccharide or
cigarette smoke extract [38], or oxidative stress via NF-κB
[39]. Importantly, elevated levels of PAI-1 in sputum have
been observed in two separate studies of patients with
COPD (compared to controls) [39,40]. Furthermore, spu-
tum PAI-1 levels were higher in more severe COPD (com-
pared to milder COPD), which would be in keeping with
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vere emphysema [40]. Other candidate emphysema sever-
ity miRNAs identified in this study – miR-34b, miR-133a/
b and miR-149 – have been previously implicated in the
pathogenesis of lung diseases. For example, miR-34b ex-
pression was decreased in induced sputum from COPD
smokers compared to non-COPD smokers [24]. Down-
regulation of miR-133a is associated with increased bron-
chial smooth muscle contraction in patients with asthma
[41]. miR-133b negatively regulates the expression of tran-
scription factor, Pitx3 [42], which activates the dopamine
receptor (DRD1), a mediator of nicotine addiction in
smokers [43]. Overall, emerging evidence of the biological
roles of these miRNAs supports the plausibility of their in-
volvement in lung diseases.
A number of potential limitations of this study should
be addressed. (i) A physiological measure of emphysema
(gas transfer) was used to stratify patients, as in our pre-
vious study [18], rather than pathological examination of
lung tissue. The reason for this was that these lung tis-
sue samples were not inflated at harvesting, making
morphological assessment of emphysema severity diffi-
cult. However, gas transfer is routinely used clinically as
a measure of emphysema severity in COPD patients.
(ii) Although a relatively small number of samples was
used (from 29 patients), the FDRs of the 5 miRNAs were
all <0.05; furthermore, the two miRNAs tested (miR-34c
and miR-133a) were technically validated independently
using qRT-PCR. (iii) No overlap was found between the
miR-34c targets that were enriched in ex vivo lung sam-
ples and in vitro cell lines. It should be noted that the
ex vivo study used Operon microarrays which repre-
sented only 14,000 genes. Furthermore, our in vitro
study used commercial cell lines, and all of our COPD
lung samples were from patients who also had lung can-
cer. Despite these potential limitations, we found that
the expression of five candidate genes in vitro correlated
with ex vivo profiles in both in-house [18] and external
datasets (Spira et al. [19]).
Conclusion
In summary, miRNA expression is associated with increa-
sing emphysema severity in COPD patients. Increasing
miR-34c expression in vitro in respiratory cell lines de-
creased the expression of its predicted targets, consistent
with miRNA-mediated regulation of mRNA. Additionally,
we have shown by qRT-PCR that SERPINE1 expression is
increased in lung from patients with increasing severity of
emphysema, in whom miR-34c expression is low. Future
studies should aim to directly demonstrate miR-34c-
mediated SERPINE1 regulation in emphysema and eva-
luate the pathogenetic role of other miRNAs, with the goal
of identifying potentially important targets for more effect-
ive treatment of COPD.Availability of supporting data
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arrays. Raw signal intensity of all 550 miRNAs is shown for the replicate
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differentially expressed between mild and moderate emphysema
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